The First Affiliated Hospital of USTC
Hefei, Anhui, 230001, China
Location status: Recruiting
Location contact
Tingting Zhao, Master
CONTACT
Yingying Wang, Doctor
CONTACT
Recruiting
NCT Number: NCT06405945
Cervical Cancer Susceptible Population Classification
Cervical cancer is the third most common lethal tumor globally, causing around a quarter million deaths annually, despite the availability of HPV vaccines. Recent Genome-wide association studies (GWAS) have identified numerous genetic markers linked to cervical cancer, including rs10175462, rs10007915, rs35721900, and rs61646675, which have been verified as being related to susceptibility to cervical cancer. However, many reports lack clarity, consistency, and validation. In this comprehensive study, we will analyze the genomic risk factors associated with cervical cancer, classify individuals into different risk categories, and explore potential biomarkers and therapeutics.
Recruiting
Interested in participating?
Request InfoKey information
Age range
18 year and older
Sex eligibility
Female
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Subjects aged >=18 years at time of consent
- Intended to undergo screening colposcopy
- Considered by a physician or healthcare provider as being of "average risk" for cervical cancer
- Willing to consent to blood draw cervical disease treatments
- Willing to sonsent to follow-up for five years as per protocol
Exclusion criteria
- History of cervical cancer
- History of any malignancy (patients who have undergone surgical removal of skin squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of informed consent for the study)
- Currently taking any anti-neoplastic or disease-modifying anti-rheumatic drugs.
- Any major physical trauma (e.g. disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent
- Known medical condition which, in the opinion of the investigator, should preclude enrollment into the study
Treatment and study plan
PCR and sequence
Geneticsequence the mutatation SNPs
Primary outcomes
-
Evalutaiton of the SNPs test in an average cervical cancer patients screening episode
Time frame: two years
Secondary outcomes
-
Classified susceptied person into different ladders
Time frame: two years
Study contacts
Contact information is provided by the study sponsor or research team.
Tingting Zhao, Master
CONTACT
Yingying Wang, Doctor
CONTACT
Sponsors and collaborators
Lead sponsor
Anhui Provincial Hospital
Other Gov
Registry information
Official study title
Evalutaion of the SNPs Test in Average Cervical Cancer Screening Episode
Important dates
- Study start
- 2024
- Primary completion
- 2034
- Study completion
- 2036
- First posted
- May 9, 2024
- Registry last updated
- May 9, 2024
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.